Nektar Therapeutics (NKTR) Tops Q1 EPS by 97c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
Revenue Growth %: -7.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.73, $0.97 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.11 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
